NIH Funding Opportunities

Subscribe to NIH Funding Opportunities feed
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 7 hours 5 min ago

Limited Competition: RCMI Research Coordination Network (RRCN) (U54 Clinical Trial Not Allowed)

Fri, 08/17/2018 - 10:20
Funding Opportunity RFA-MD-18-011 from the NIH Guide for Grants and Contracts. The RCMI Research Coordination Network (RRCN), formerly known as the RCMI Translational Research Network (RTRN), was established in 2007 to enhance collaboration across RCMI institutions. The network is designed to engage all stakeholders in the RCMI institutions, increase the quality and efficiency of basic biomedical, behavioral, and clinical research, facilitate study participant recruitment and retention, and increase the efficiency of the implementation and dissemination of research advances to improved health outcomes among minority and health disparity populations. Maintaining the longstanding networking and collaboration with the RCMI grantee community is key to the continued success of this program. The purpose of this funding opportunity announcement (FOA) is to provide infrastructure and research funding to support overall network coordination and collaboration, and to expand the Research Coordinating Center (RCC) and Data Coordinating Center (DCC) functions of the RRCN. Applications responding to this FOA are limited to grantees currently funded via the RCMI program in response to PAR-11-132, PAR-13-279 and RFA-MD-17-003.
Categories: Science RSS Feeds

NLM Information Resource Grants to Reduce Health Disparities (G08 Clinical Trial Not Allowed)

Thu, 08/16/2018 - 10:41
Funding Opportunity RFA-LM-19-001 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits resource grant applications for projects that will bring useful, usable health information to health disparity populations and their health care providers. Access to useful, usable, understandable health information is an important factor when making health decisions. Proposed projects should exploit the capabilities of computer and information technology and health sciences libraries to bring health-related information to consumers and their health care providers. Because this FOA focuses on providing health information to health disparity populations, institutions with demonstrated commitment to the needs of health disparity communities (including Tribal Colleges and Universities (TCU), Historically Black Colleges and Universities (HBCU), Hispanic-Serving Institutions (HSI) and other institutions in rural and socially disadvantaged areas) are encouraged to apply.
Categories: Science RSS Feeds

Leveraging Electronic Medical Records for Psychiatric Genetic Research (R01 Clinical Trial Not Allowed)

Thu, 08/16/2018 - 09:58
Funding Opportunity PAR-18-904 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support projects that implement creative, efficient molecular epidemiologic approaches that incorporate individual genetic information, including polygenic as well as specific genetic risk variants, in existing large, population-based cohorts, registries and/or health systems to conduct analyses that advance our understanding of the complex etiology of severe mental disorders. The ultimate objective of this funding opportunity is the elucidation of the complex interplays of genetic (e.g., polygenic) risk, in addition to specific risk loci and networks, and environmental factors, in human populations, which will lead to better understanding, diagnosis, and ultimately treatment of mental disorders.
Categories: Science RSS Feeds

Leveraging Electronic Medical Records for Psychiatric Genetic Research (R01 (Collab) Clinical Trial Not Allowed)

Thu, 08/16/2018 - 09:58
Funding Opportunity PAR-18-905 from the NIH Guide for Grants and Contracts. The ultimate objective of this funding opportunity is the elucidation of the complex interplays of genetic (e.g., polygenic) risk, in addition to specific risk loci and networks, and environmental factors, in human populations, which will lead to better understanding, diagnosis, and ultimately treatment of mental disorders. For a linked set of collaborative R01s, each site has its own Program Director(s)/Principal Investigator(s), and the program provides a mechanism for cross-site coordination and communication. Collaborative studies are appropriate to address research projects that go beyond the capacity of a single-site investigation, particularly to accommodate collaborations among sites with diverse expertise, perspectives, and contributions.?Specifically, the purpose of this funding opportunity announcement (FOA) is to support collaborative R01 projects from multidisciplinary teams that implement creative, efficient molecular epidemiologic approaches that incorporate individual genetic information, including polygenic as well as specific genetic risk variants, in existing large, population-based cohorts, registries and/or health systems to conduct analyses that advance our understanding of the complex etiology of severe mental disorders. Applicants wishing to submit individual l projects should apply to the companion FOA (link).
Categories: Science RSS Feeds

Research Network on Telomeres as Sentinels of Environmental Exposures, Psychosocial Stress, and Disease Susceptibility (U24 Clinical Trial Not Allowed)

Wed, 08/15/2018 - 08:46
Funding Opportunity RFA-AG-19-022 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement invites applications for a U24 Telomere Research Network/Collaboratory. This U24 will coordinate activities of a telomere length (TL) methods comparison study involving multiple labs supported under U01 awards made in response to FOA (RFA-AG-19-023) to address the need for cross-validation between protocols and samples for establishing best practices for population-based TL research. The U24 will serve as the central resource for the organization of meetings and other activities of this coordinated program, including support for the methods study, dissemination of its results and resultant recommendations. It will also develop and foster an extended Telomere Research Network (TRN) connecting the broader field through a flexible range of activities that will advance an interdisciplinary research agenda on telomeres and activities directly associated with TL maintenance as sentinels of environmental exposures, psychosocial stress, and disease susceptibility.
Categories: Science RSS Feeds

Telomeres as Sentinels of Environmental Exposures, Psychosocial Stress, and Disease Susceptibility: A Methods Comparison Study (U01 Clinical Trial Optional)

Wed, 08/15/2018 - 08:46
Funding Opportunity RFA-AG-19-023 from the NIH Guide for Grants and Contracts. This U01 Cooperative Agreement Funding Opportunity Announcement (FOA) will support 3-4 U01 Methods Comparison Projects to serve three main functions: (1) to conduct a joint effort among telomere researchers to determine the relationship between different telomere length (TL) methods, inter-assay variability, and the factors that influence results; (2) Contribute to development of best practice recommendations for assay protocols for TL measurement for different types of studies, with a focus on population-based health research, including biological sample collection, storage, and processing; laboratory methods; data analysis; and reporting requirements; and (3) Repurpose existing methods or develop new methods to enhance the use of TL measurement. The U01 Methods Comparison Projects will be expected to conduct cross-validation involving other labs (3-4) supported under this cooperative agreement to develop a set of recommendations for assay protocols for telomere measurement for different types of studies and development of best practice guidelines for population-based TL research. This will be done in coordination with the U24 Telomere Research Network/Collaboratory award made in response to FOA (RFA-AG-19-022). Please refer to the NIA website regularly for updates, frequently asked questions (FAQs), and other announcements related to this FOA and the companion FOA.
Categories: Science RSS Feeds

Pilot and Feasibility Clinical and Translational Research Studies in Digestive Diseases and Nutrition (R21 Clinical Trial Optional)

Tue, 08/14/2018 - 11:34
Funding Opportunity PA-18-903 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to foster the advancement of the research mission of the Division of Digestive Diseases and Nutrition, NIDDK by soliciting research concepts that for pilot and feasibility clinical study proposals would need further assessment of identified protocol operational challenges would enhance operational feasibility of achieving successful completion of a subsequent larger clinical study; or for clinical translational science proposals, promote exploratory and novel science through the use of human subjects. The following studies will not be supported by this FOA: those that have obesity as a component of the study proposal (please refer to the Office of Extramural Research Grants and Funding to search for multiple obesity related Funding Opportunity Announcements at https://grants.nih.gov/grants/oer.htm); and translational studies that utilize animal models.
Categories: Science RSS Feeds

Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Optional)

Tue, 08/14/2018 - 11:12
Funding Opportunity PA-18-902 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is twofold: 1. to accelerate translational and clinical Phase I and II a/b safety and efficacy studies for substantiating measurable functional benefits of probiotic/prebiotic components and/or their combinations; and; 2. to understand the underlying mechanisms of their action(s), and variability in responses to these interventions. This FOA calls for interdisciplinary collaborations across scientific disciplines engaged in microbiome and pro/prebiotic research including, but not limited to: nutritional science, microbiology, virology, microecology and microbiome, genomics, immunology, computational biology, chemistry, bioengineering, as well as integration of omics and computational approaches in DNA technologies. This FOA will not support phase III clinical trials.
Categories: Science RSS Feeds

Pediatric Immunotherapy Discovery and Development Network (PI-DDN)(U54 - Clinical Trial Not Allowed)

Mon, 08/13/2018 - 10:06
Funding Opportunity RFA-CA-19-003 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to establish centers of collaborating investigators with the goal of identifying and advancing research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translational science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system. The Pediatric Immunotherapy Discovery and Development Network (PI-DDN) Centers will address and implement these BRP recommendations.
Categories: Science RSS Feeds

Pediatric Immunotherapy Discovery and Development Network (PI-DDN)(U01 - No Clinical Trial Allowed)

Mon, 08/13/2018 - 10:06
Funding Opportunity RFA-CA-19-004 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The overall goal of this FOA and the companion FOA, RFA-CA-19-012, is to establish a network of collaborating investigators to identify and advance research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translation science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system. This FOA solicits U01 applications for discrete research projects that address relevant research opportunities (e.g., mechanisms of immune evasion, model development, validation of a single target, etc.), whereas the companion FOA, RFA-CA-19-003, solicits multi-component U54 Center applications. Successful applicants from both FOAs will become members of the Pediatric Immunotherapy Discovery and Development Network (PI-DDN), which will address and implement the BRP recommendations.
Categories: Science RSS Feeds

Chronic, Non-Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award (NCD-LIFESPAN) (D43)(Clinical Trial Optional)

Mon, 08/13/2018 - 02:17
Funding Opportunity PAR-18-901 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages applications for the Chronic, Non-Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award (NCD-LIFESPAN) D43 program for institutional research training programs in low-and middle-income countries (LMICs, as defined by the World Bank classification system). Applications may be for collaborations between institutions in the U.S and an eligible LMIC or may involve just LMIC institutions if there is a previous track record of externally funded research and/or research training programs by the lead LMIC institution. The proposed institutional research training program is expected to sustainably strengthen the NCD research capacity of the LMIC institutions, and to train in-country experts to develop and conduct research on NCDs across the lifespan, with the long-range goal of developing and implementing evidence-based interventions relevant to their countries. The main focus of research training covered in the application must be relevant to the interests of at least one of the participating NIH ICs as stated by each in this FOA. Other NCD topics may be included as secondary and complementary focus areas.
Categories: Science RSS Feeds

Pre-Application: Research Innovation for Scientific Knowledge (RISK) for Skin and Rheumatic Diseases (X02 Clinical Trial Not Allowed)

Fri, 08/10/2018 - 11:39
Funding Opportunity PAR-18-899 from the NIH Guide for Grants and Contracts. The NIAMS Research Innovation for Scientific Knowledge (RISK) for Skin and Rheumatic Diseases initiative focuses on innovative research within the NIAMS mission by encouraging applicants to pursue unusual observations, test imaginative hypotheses, investigate creative concepts, and build ground-breaking paradigms, all of which deviate significantly from the current prevailing theories or practice. This FOA is particularly designed to encourage the submission of projects that are considered too risky, premature, controversial, or unconventional for other NIH mechanisms. This FOA intends to support disease-focused translational studies. We invite research studies aimed at understanding the mechanisms of diseases or conditions relevant to the NIAMS mission, as well as studies aimed at developing or testing diagnostics, therapeutic agents, or preventive interventions up to, but not including, first in human studies. The RISK X02 and R61/R33 FOAs are not intended to support clinical trials. The RISK program will support the two main scientific areas of NIAMS mission, 1) musculoskeletal diseases and 2) the skin and rheumatic diseases. This X02 pre-application and the companion R61/R33 (RFA- AR-19-012) encourage applications related to skin and rheumatic diseases. The X02 pre-application is the highly recommended (not required) first step in the application process for the companion R61/R33 (RFA-AR-19-012). Potential applicants should read both FOAs. Investigators whose X02 pre-applications are evaluated to be highly innovative and most relevant to the RISK program will be notified of the opportunity to submit an R61/R33 application under RFA-AR-19-012.
Categories: Science RSS Feeds

Findings of Research Misconduct

Fri, 08/10/2018 - 11:27
Notice NOT-OD-18-216 from the NIH Guide for Grants and Contracts
Categories: Science RSS Feeds

Pages